ESG
Built with purpose. Measured by impact.
Helping people keep to their medication is the point of the company. Here is how we approach the environment, people and governance.
Our commitment
Kwelio exists to help people keep to the medicines that keep them well, and to show their insurers who may need support. We measure success by that as well as by commercial results.
We are building first in the UAE and the wider GCC.
- Environmental
Digital first
Kwelio is a software platform by design: the app and Kwelix run in the cloud, and members use the phone they already have.
- Social
Support where it matters
Non-adherence is associated with up to 10% of US hospital admissions, and accounts for 33–69% of medication-related hospitalisations. Kwelio helps care teams reach the members who may need support first.
- Governance
Privacy-first architecture
Lumio Holdings Limited (ADGM) is the data controller and Kwelio Labs FZ LLC (Dubai Media City) the processor. We name each law that applies: the UAE Federal PDPL (45/2021), the ADGM Data Protection Regulations 2021, and the GDPR where it applies.
Social impact
The people Kwelio is built to serve.
- 50%
In developed countries, adherence to long-term therapy for chronic illness averages around 50%.WHO, 2003
- 20.7%
of UAE adults live with diabetes on an age-adjusted basis — among the highest prevalence rates in the world.IDF, 2024
- AED 39.9bn
Non-communicable disease cost the UAE an estimated AED 39.9 billion in 2019, of which around AED 26 billion was cardiovascular disease.
Data and privacy
How we handle your data
- Never sold
- We do not sell personal data, and we do not share it with advertisers.
- What insurers see
- A member’s medication score and whether they might need support. Never photos or daily dose logs, and individual reasons only with the member’s consent to outreach.
- Your rights
- Members can ask to see, correct or delete their data at any time by writing to privacy@kwelio.com.